Trial Information - Phase II
A Single-Arm, Open-Label, Multicenter Phase 2 Study toEvaluate the Efficacy, Safety, and Pharmacokinetics ofBcl-2 Inhibitor BGB-11417 in Patients With Relapsed orRefractory Mantle Cell Lymphoma
Disease Specifics: (Mantle Cell)
Protocol ID: BGB-11417-201
Sponsor: BeiGene USA Inc.
Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at
877-664-7724
